Aptose Biosciences (TSE:APS) Reaches New 12-Month Low at $0.77

Shares of Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) hit a new 52-week low on Monday . The stock traded as low as C$0.77 and last traded at C$0.77, with a volume of 6439 shares traded. The stock had previously closed at C$0.77.

Aptose Biosciences Stock Down 1.3 %

The business has a 50-day moving average price of C$1.16 and a 200-day moving average price of C$1.84. The stock has a market cap of C$12.40 million, a PE ratio of -0.07 and a beta of 1.47. The company has a current ratio of 0.78, a quick ratio of 5.41 and a debt-to-equity ratio of 14.27.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last released its earnings results on Tuesday, May 14th. The biotechnology company reported C($0.98) earnings per share for the quarter, beating the consensus estimate of C($1.12) by C$0.14. As a group, analysts forecast that Aptose Biosciences Inc. will post -0.59 earnings per share for the current year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.